ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Operating Income
ScinoPharm Taiwan Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Operating Income
NT$446.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-6%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Operating Income
NT$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Operating Income
NT$701.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
100%
|
CAGR 10-Years
9%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Operating Income
NT$159.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-5%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Operating Income
NT$5.1B
|
CAGR 3-Years
30%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Operating Income
NT$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Operating Income?
Operating Income
446.4m
TWD
Based on the financial report for Sep 30, 2024, ScinoPharm Taiwan Ltd's Operating Income amounts to 446.4m TWD.
What is ScinoPharm Taiwan Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-6%
Over the last year, the Operating Income growth was 80%. The average annual Operating Income growth rates for ScinoPharm Taiwan Ltd have been 22% over the past three years , 4% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet